Drug Pipeline
Subscribe to Drug Pipeline

The Lead

GeoVax HIV Vaccine Moves Forward

April 1, 2015 1:40 pm | News | Comments

GeoVax Labs, a biotechnology company developing human vaccines for Ebola and HIV, today announced that the HIV Vaccine Trials Network (HVTN) has assigned a trial number, HVTN 114, to the next clinical trial of its clade B preventive HIV vaccine candidate. Read more...

Merck's HPV Vaccine Now Available in Canada

April 1, 2015 10:12 am | News | Comments

Merck, known as MSD outside the United States and Canada, announced that Gardasil 9 (Human ...

U.S. RA Treatment Market to Reach $9.3B by 2020

April 1, 2015 10:03 am | News | Comments

The US treatment market for Rheumatoid Arthritis (RA) is set to increase in value from $6.4...

BioDelivery Sciences’ Pain Treatment Fails Study

March 30, 2015 3:46 pm | by Stephanie Guzowski, Editor | News | Comments

BioDelivery Sciences International Inc. said on Monday its pain drug for diabetic neuropathy...

View Sample

FREE Email Newsletter

Daily news and top headlines for drug research professionals

Novartis, Aduro: Up-to-$750M Cancer Immunotherapy Collaboration

March 30, 2015 12:52 pm | by Stephanie Guzowski, Editor | News | Comments

Novartis is planning to boost its cancer immunotherapy pipeline with a collaboration with California-based Aduro Biotech worth up to $750 million. Read more...

White House Releases Plan to Fight Antibiotic Resistance

March 27, 2015 12:58 pm | by Stephanie Guzowski, Editor | News | Comments

The White House has revealed today its comprehensive plan to tackle antibiotic resistance within the next five years, according to a copy of the 60-page report, which was reviewed by Reuters. Read more...

FDA Approves Anthrax Treatment

March 25, 2015 1:10 pm | by Stephanie Guzowski, Editor | News | Comments

The Food and Drug Administration (FDA) yesterday approved Emergent BioSolutions’ infusible drug Anthrasil for use in combination with antibiotics to treat inhalational anthrax, which happens when bacterial spores that carry anthrax are breathed in. Read more...


Antibiotics Pipeline Boasts 741 Products, but First-in-class Development Remains Low: GBI Research

March 25, 2015 9:48 am | News | Comments

While antibiotics boast a vast pipeline, with 741 products currently in development, the majority is dominated by generics, as weak financial incentives and high failure rates have discouraged innovation, says business intelligence provider GBI Research. Read more..

Pfizer, Lilly To Resume Phase 3 Chronic Pain Program For Tanezumab

March 24, 2015 12:37 pm | News | Comments

Pfizer Inc. and Eli Lilly and Company announced that they are preparing to resume the Phase 3 clinical program for tanezumab. Read more...

FDA Panel Backs GSK Inhaler for Adults, Not Adolescents

March 20, 2015 9:47 am | by Matthew Perrone, AP Health Writer | News | Comments

Government health advisers say a once-a-day respiratory inhaler from GlaxoSmithKline appears safe and effective for adults with asthma, but not for adolescents. Read more...

Targeted Drug Doubles Progression Free Survival in Hodgkin Lymphoma

March 19, 2015 12:57 pm | News | Comments

A phase 3 trial of brentuximab vedotin (BV), the first new drug for Hodgkin lymphoma in over 30 years, shows that adults with hard-to-treat Hodgkin lymphoma given BV immediately after stem cell transplant survived without the disease progressing for twice as long as those given placebo (43 months vs 24 months). Read more...

AstraZeneca’s COPD Drug: Promising Phase 3 Study

March 18, 2015 1:16 pm | by Stephanie Guzowski, Editor | News | Comments

AstraZenca’s experimental drug, PT003, for chronic obstructive pulmonary disease (COPD) has had successful results in two final-stage Phase 3 trials (24-week studies PINNACLE 1 and PINNACLE 2). Read more...


Amgen's Cholesterol-Lowering Repatha Shows Positive Data

March 16, 2015 10:19 am | News | Comments

Amgen announced new detailed data from the Phase 3 YUKAWA-2 study evaluating Repatha (evolocumab), a novel investigational cholesterol-lowering medication, in Japanese patients with high cardiovascular risk and high cholesterol.  Read more...

Immunotherapy: New Hope for Patients with Advanced Lung Cancer

March 13, 2015 11:52 am | by Columbia University | News | Comments

In the late 1800s, a New York surgeon named William Coley noticed that some patients with cancer seemed to fare better if they developed an infection after undergoing surgery. Suspecting that the immune system played a role in this mysterious response, he tried treating cancer patients with bacteria in an effort to turn on the immune system. Read more...

FDA Approves Pediatric Cancer Drug

March 11, 2015 4:24 pm | by Stephanie Guzowski, Editor | News | Comments

The U.S. Food and Drug Administration (FDA) has approved Unituxin (dinutuximab), part of a first-line therapy for high-risk neuroblastoma. Read more..                                  

Breakthrough Therapies Target Cancers in 2015

March 11, 2015 8:57 am | by Bevin Fletcher, Associate Editor, Bioscience Technology | Articles | Comments

Getting a new drug to market is difficult, but the U.S. Food and Drug Administration (FDA) offers a number of ways to help the process along for promising drugs that have potential against serious diseases. Read more...

Orexo U.S. Launches New Dosage of Opioid Dependence Drug

March 9, 2015 10:07 am | News | Comments

​Orexo US, Inc. (Orexo) announced that following U.S. Food and Drug Administration (FDA) approval, the new 8.6mg/2.1mg dosage strength of Zubsolv is now available.  Read more...


FDA Approves Actavis', Medicines360's Long-Term Contraception

March 2, 2015 10:06 am | News | Comments

Actavis plc, a leading global specialty pharmaceutical company, and Medicines360, a nonprofit women's health pharmaceutical company, announced the approval of Liletta (levonorgestrel-releasing intrauterine system) by the U.S. Food and Drug Administration (FDA) for use by women to prevent pregnancy for up to three years. Read more...

First Treatment Approved in Canada for Adults With ADPKD

March 2, 2015 9:52 am | News | Comments

Otsuka Pharmaceutical Co., Ltd. and its affiliate Otsuka Canada Pharmaceutical Inc. announce that Health Canada has approved JINARC (tolvaptan) as the first pharmaceutical agent for the treatment of autosomal dominant polycystic kidney disease (ADPKD). Read more...

Sanofi Gets FDA Approval for New Insulin Drug

February 26, 2015 12:06 pm | by Stephanie Guzowski, Editor | News | Comments

Sanofi announced late Wednesday that it received approval from the U.S. Food and Drug Administration (FDA) to sell its new insulin product Toujeo. The once-daily, long-acting basal insulin will help improve glycemic control in adults with type 1 and type 2 diabetes. Read more..

Amgen: Positive Results for CKD Treatment

February 26, 2015 11:05 am | News | Comments

Amgen announced results from the head-to-head Phase 3 study comparing AMG 416 with cinacalcet for the treatment of secondary hyperparathyroidism (SHPT) in patients with chronic kidney disease (CKD) receiving hemodialysis. Read more...

Ampio: Results of Injections STRUT Study

February 25, 2015 10:11 am | by Ampio Pharmaceuticals | News | Comments

Ampio Pharmaceuticals, Inc. announced results of the double-blind, multiple injection, vehicle controlled STRUT study (N=40) at 20 weeks. Read more..

BioDelivery Sciences to Receive $10M from Endo Pharmaceuticals

February 23, 2015 10:56 am | News | Comments

BioDelivery Sciences International, Inc. and Endo Pharmaceuticals Inc., a subsidiary of Endo International plc announced that the U.S. Food and Drug Administration (FDA) accepted the New Drug Application (NDA) for Belbuca. Read more..

Asthma Drug Improves Lung Function: Phase 3 Data

February 23, 2015 10:13 am | News | Comments

Boehringer Ingelheim today presented data on investigational tiotropium delivered via Respimat inhaler from five Phase 3 trials from the UniTinA-asthma program at the 2015 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting in Houston, Texas. Read more..

Oral Med Shows Promise in Hormone-Resistant Breast Cancer

February 23, 2015 10:03 am | News | Comments

​Palbociclib, an investigational oral medication that works by blocking molecules responsible for cancer cell growth, is well tolerated and extends progression-free survival (PFS) in newly diagnosed, advanced breast cancer patients, including those whose disease has stopped responding to traditional endocrine treatments. Read more...

Lilly Provides Update on Evacetrapib Phase 3 Trial

February 20, 2015 12:25 pm | News | Comments

Eli Lilly and Company has accepted the recommendation of the ACCELERATE study academic executive committee, based on emerging science in the cardiovascular field, to extend the Phase 3 trial of the investigational medicine evacetrapib by approximately six months. Read more....

FDA Expands Indications for Revlimid

February 18, 2015 10:40 am | by Associated Press | News | Comments

Celgene Corporation announced that the U.S. Food and Drug Administration (FDA) has expanded the existing indication for Revlimid (lenalidomide) in combination with dexamethasone to include patients newly diagnosed with multiple myeloma (NDMM). Read more..

Lupin, Celon: Development, Licensing for Generic Advair Diskus

February 17, 2015 10:02 am | News | Comments

​Pharma Major Lupin Limited (Lupin) and Celon Pharma S.A. (Celon) announced that they have entered into a definitive agreement under which the companies will jointly develop a fluticasone/salmeterol dry powder inhaler (DPI) product which is a generic version of GlaxoSmithKline's Advair Diskus. Read more...

Drug Abuse in Iran Rising Despite Executions, Police Raids

February 13, 2015 10:34 am | by Ali Akbar Dareini - Associated Press | News | Comments

Officials say methamphetamine production and abuse of hard drugs are skyrocketing in the country despite potentially lethal criminal penalties for users if they are caught. Read more...            

You may login with either your assigned username or your e-mail address.
The password field is case sensitive.